RAC 5.06% $1.69 race oncology ltd

...Unless we think we can get IND approval from the P1 data...

  1. 457 Posts.
    lightbulb Created with Sketch. 689
    ...Unless we think we can get IND approval from the P1 data (CPACS).

    Primary endpoints: Safety & optimal Phase 2 dose
    Exploratory endpoints: Standard & advanced cardiac markers including VO2Peak, m6A RNA levels, & anticancer efficacy
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.